These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 21451262)
21. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Sims RB Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856 [TBL] [Abstract][Full Text] [Related]
22. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? Moyad MA Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606 [TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Lü C; Williams AK; Chalasani V; Martínez CH; Chin J Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858 [TBL] [Abstract][Full Text] [Related]
24. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Cheever MA; Higano CS Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425 [TBL] [Abstract][Full Text] [Related]
25. [Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer]. Kubáčková K Klin Onkol; 2015; 28 Suppl 4():4S69-72. PubMed ID: 26647892 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Harzstark AL; Small EJ Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825 [TBL] [Abstract][Full Text] [Related]
28. Cellular immunotherapy licensed for advanced prostate cancer. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204 [No Abstract] [Full Text] [Related]
29. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Arlen PM Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469 [No Abstract] [Full Text] [Related]
30. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product. Baghdadi R Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168 [No Abstract] [Full Text] [Related]
32. Immunotherapy: a new option for advanced prostate cancer. Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869 [No Abstract] [Full Text] [Related]
35. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Gardner TA; Elzey BD; Hahn NM Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254 [TBL] [Abstract][Full Text] [Related]
36. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Patel PH; Kockler DR Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines. Patel A; Fong L Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065 [TBL] [Abstract][Full Text] [Related]
38. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512 [TBL] [Abstract][Full Text] [Related]
39. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902 [TBL] [Abstract][Full Text] [Related]
40. Prostate cancer vaccines. Michael A; Relph K; Annels N; Pandha H Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]